Literature DB >> 26676829

1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).

Jian Huang1, Guozhen Yang2, Yunzhu Huang3, Weiying Kong1, Shu Zhang2.   

Abstract

Vitamin D, termed 1,25(OH)2D3 in it's active form, activity is associated with a reduced risk of hepatocellular carcinoma (HCC) and is an important immune regulator. However, the detail molecular mechanisms underlying the effects of 1,25(OH)2D3 on the progression of HCC are widely unknown. Histone deacetwylase 2 (HDAC2) is usually expressed at high levels in tumors, and its downregulation leads to high expression levels of cell cycle components, including p21(WAF1/Cip1), a well-characterized modulator, which is critical in cell senescence and apoptosis. The present study investigated whether vitamin D inhibits HCC via the regulation of HDAC2 and p21(WAF1/Cip1). Firstly, the toxic concentrations of 1,25(OH)2D3 were determined, according to trypan blue and [(3)H]thymidine incorporation assays. Secondly, HCC cells lines were treated with different concentrations of 1,25(OH)2D3. The expression of HDAC2 was either silenced via short hairpin (sh)RNA or induced by transfection of plasmids expressing the HDAC2 gene in certain HCC cells. Finally the mRNA and protein levels of HDAC2 and p21(WAF1/Cip1) were measured using reverse transcription-quantitative polymerase chain reaction and western blot analyses. The results revealed that 1,25(OH)2D3 treatment reduced the expression of HDAC2 and increased the expression of p21(WAF1/Cip1), in a dose-dependent manner, resulting in the reduction of HCC growth. Elevated levels of HDAC2 reduced the expression of p21(WAF1/Cip1), resulting in an increase in HCC growth. HDAC2 shRNA increased the expression of p21(WAF1/Cip1), resulting in reduction in HCC growth. Thus, 1,25(OH)2D3 exerted antitumorigenic effects through decreasing the expression levels of HDAC2 and increasing the expression of p21(WAF1/Cip1), which inhibited the development of HCC and may indicate the possible underlying mechanism. These results suggest that vitamin D3 may be developed as a potential drug for effective therapy in the treatment of HCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26676829     DOI: 10.3892/mmr.2015.4676

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system.

Authors:  Mercedes Garcia-Gil; Federica Pierucci; Ambra Vestri; Elisabetta Meacci
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

Review 2.  Histone deacetylase‑2: A potential regulator and therapeutic target in liver disease (Review).

Authors:  Ya-Ru Liu; Jie-Quan Wang; Zhao-Gang Huang; Ruo-Nan Chen; Xi Cao; Dong-Chun Zhu; Hai-Xia Yu; Xiu-Rong Wang; Hai-Yun Zhou; Quan Xia; Jun Li
Journal:  Int J Mol Med       Date:  2021-05-20       Impact factor: 4.101

Review 3.  Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D.

Authors:  Shahida Khan; Ashraf Ali; Sarah Khan; Ahmed Bakillah; Ghazi Damanhouri; Aziz Khan; Ahmad Makki; Ibtehal AlAnsari; Naheed Banu
Journal:  Nutr Metab (Lond)       Date:  2018-02-09       Impact factor: 4.169

Review 4.  Vitamin D in liver cancer: novel insights and future perspectives.

Authors:  Antonio Markotić; Tomislav Kelava; Helena Markotić; Hrvoje Silovski; Anna Mrzljak
Journal:  Croat Med J       Date:  2022-04-30       Impact factor: 2.415

5.  Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.

Authors:  Takamasa Kobayashi; Hirokazu Kawai; Oki Nakano; Satoshi Abe; Hiroteru Kamimura; Akira Sakamaki; Kenya Kamimura; Atsunori Tsuchiya; Masaaki Takamura; Satoshi Yamagiwa; Shuji Terai
Journal:  BMC Cancer       Date:  2018-07-24       Impact factor: 4.430

6.  Serum Bioavailable, Rather Than Total, 25-hydroxyvitamin D Levels Are Associated With Hepatocellular Carcinoma Survival.

Authors:  Ai-Ping Fang; Jing-An Long; Yao-Jun Zhang; Zhao-Yan Liu; Qi-Jiong Li; Dao-Ming Zhang; Yun Luo; Rong-Huan Zhong; Zhong-Guo Zhou; Yan-Jun Xu; Xiao-Jun Xu; Wen-Hua Ling; Min-Shan Chen; Hui-Lian Zhu
Journal:  Hepatology       Date:  2020-04-03       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.